Skip to main content

How can I benefit from ADCETRIS?

Before making decisions about your treatment, see how others have responded to ADCETRIS.

Amina was treated with ADCETRIS plus AVD*

Changing your future starts with a treatment decision

ADCETRIS plus AVD helped patients with previously untreated Stage 3 or 4 classical Hodgkin lymphoma live longer compared to ABVD chemotherapy alone

In a clinical study, these patients had a 41% reduced risk of death compared to ABVD after approximately 6-years of follow-up. ADCETRIS will not work for everyone.

See study results below

Select each tab to see ADCETRIS study results for people with certain types of classical Hodgkin lymphoma

Previously untreated

Relapsed

After stem cell transplant

Previously untreated classical Hodgkin lymphoma

Study results

Side effects

ADCETRIS is used with chemotherapy (AVD) for adults treating their Stage 3 or 4 classical Hodgkin lymphoma for the first time.

1334 people.1334 people.

In ECHELON-1, a clinical study of 1334 people, ADCETRIS plus chemotherapy (AVD) was compared to
traditional treatment (ABVD).

  • 664 people received ADCETRIS plus AVD every 2 weeks for up to 6 cycles
  • 670 people received ABVD every 2 weeks for up to 6 cycles
Select the button above to view side effects.

Study results

Overall survival† rate was higher for patients treated with ADCETRIS after approximately 6 years of follow-up

Patients who were treated with ADCETRIS plus AVD had a

41%REDUCED RISK OF DEATHCompared to the ABVD group

  • About 94% of adults treated with ADCETRIS plus AVD, and about 89% of adults treated with ABVD, were still alive at 6 years
  • ADCETRIS demonstrated a higher rate of overall survival after approximately 6 years of follow-up

†Overall survival means the length of time that patients remain alive after starting study treatment.

Patients lived longer with ADCETRIS plus AVD compared to those treated with traditional ABVD chemotherapy in the ECHELON-1 study

ADCETRIS offered patients more time without cancer progression

Main study results used to support the FDA-approved use of ADCETRIS plus AVD at 2 years.

Compared to those treated with traditional ABVD chemotherapy, people treated with ADCETRIS plus AVD had:

23%REDUCED RISK OF

  • Cancer growing or spreading
  • Or receiving additional anticancer therapy
  • Or death
  • About 82% of adults treated with ADCETRIS plus AVD did not have their cancer grow or spread, need additional anticancer therapy, or die compared to about 77% of adults treated with traditional ABVD chemotherapy
  • Average follow-up time for all patients in the main study was just over 2 years (24.6 months)

At 6 years, ADCETRIS plus AVD showed continued time without cancer progression

Compared to those treated with traditional ABVD chemotherapy, people treated with ADCETRIS plus AVD had:

32%REDUCED RISK OF

  • Cancer growing or spreading
  • Or death
  • About 82% of adults treated with ADCETRIS plus AVD did not have their cancer grow or spread, or die compared to about 75% of those treated with ABVD
  • These results are from an exploratory analysis. This means that the study was not designed to find differences or benefits between the 2 groups at this time point (at 6 years). Conclusions cannot necessarily be based on this information

For additional 6-year follow-up data, review the treatment decision guide so you can feel confident discussing options with your doctor.

View Treatment Decision Guide

Find out if ADCETRIS may be an option for you.

Glossary

ABVD: A combination of 4 chemotherapies—Adriamycin, bleomycin, vinblastine, and dacarbazine.

AVD: A combination of 3 chemotherapies—Adriamycin, vinblastine, and dacarbazine.

FDA: Food and Drug Administration.

Overall survival: The length of time that patients remain alive after starting study treatment.

Amina chose ADCETRIS

Amina chose ADCETRIS

Amina and her doctor considered effectiveness, safety, and potential long-term impacts before choosing ADCETRIS plus AVD.

Watch the video

The science of ADCETRIS treatment

ADCETRIS is not like traditional chemotherapy. It is an antibody drug conjugate made up of 3 parts: an antibody, a drug, and a linker.

Antibody

An antibody that finds CD30, a protein on the surface of certain cells. Antibodies are proteins made by the body’s immune system. The antibody that makes up ADCETRIS is made in a laboratory.

Drug

A drug that is designed to cause cell death.

Linker

A linker that attaches the drug to the antibody and releases the drug inside the cell.

How does ADCETRIS work?

ADCETRIS attaching to cell via CD30 protein.

Step 1

ADCETRIS aims to attach to cells that have a protein on their surface called CD30.

ADCETRIS is released inside the cell.

Step 2

Once attached, ADCETRIS is brought into the cell and released.

Cell death.

Step 3

The drug stops the cell from being able to grow and divide, causing the cell to die.

CD30 is found on classical Hodgkin lymphoma cells and not commonly found on healthy cells. Even though ADCETRIS is a CD30-directed therapy, it can still harm normal cells and cause side effects. Talk to your doctor if you have questions about possible side effects.

Treatment Decision Guide

Questions for your doctor

*Amina was compensated for her participation in this campaign.